Chemical inhibition of a bacterial immune system
Cell Host & Microbe · 2026-02 · 34 (2) · 263-277.e11
DOI: 10.1016/j.chom.2026.01.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2026-02. Verfasst von Zhiyu Zang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indiana University Bloomington, Bloomington, IN 47405, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Bacteriophages, Bacteria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
The rise of antibiotic resistance motivates a revived interest in phage therapy. However, bacteria possess dozens of anti-phage immune systems that confer resistance to therapeutic phages. Chemical inhibitors of these anti-phage immune systems could be employed as adjuvants to overcome resistance in phage-based therapies. Here, we report a class of chemical inhibitors that selectively inhibit type II Thoeris anti-phage immune systems from diverse bacteria-including antibiotic-resistant pathogens, thereby sensitizing phage-resistant bacteria to phages. These inhibitors block the biosynthesis of a histidine-ADPR intracellular "alarm" signal by ThsB, thereby preventing ThsA from arresting phage replication. Chemical inhibition of the Thoeris defense improves the efficacy of a model phage therapy against a phage-resistant clinical isolate of P. aeruginosa in a mouse infection, suggesting a therapeutic potential. These findings demonstrate that the selective inhibition of anti-phage defense systems can improve the efficacy of therapeutic phages, suggesting a strategy to circumvent phage-therapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Indiana University Bloomington, Bloomington, IN 47405, USA.
- Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius 10257, Lithuania.
- Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
- Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, QLD 4215, Australia.
- Department of Microbiology, College of Basic Medical Sciences, Key Laboratory of Microbial Engineering Committee in Chongqing, Army Medical University, Chongqing 400038, China.
- Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA.
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NCATS NIH HHS
- Camille and Henry Dreyfus Foundation Inc
- National Institutes of Health
- Australian Research Council
- Key Technologies Research and Development Program
- Robert J Kleberg Jr and Helen C Kleberg Foundation
Zitieren
APA
Zang, Z., Duncan, O. K., Sabonis, D., Fedorova, I., Shi, Y., Miraj, G., Le, S., Deng, J., Zhu, Y., Cai, Y., Zhang, C., Arya, G., Dixon, S. A. H., Angus, S. P., Duerkop, B. A., Liang, H., Pepin, R. H., Ve, T., Bondy-Denomy, J., …, & Gerdt, J. P. (2026). Chemical inhibition of a bacterial immune system. Cell Host & Microbe, 34(2), 263-277.e11. https://doi.org/10.1016/j.chom.2026.01.003
Vancouver
Zang Z, Duncan OK, Sabonis D, Fedorova I, Shi Y, Miraj G, et al. Chemical inhibition of a bacterial immune system. Cell Host & Microbe. 2026;34(2):263-277.e11. doi:10.1016/j.chom.2026.01.003
BibTeX
@article{Zang2026,
author = {Zang, Zhiyu and Duncan, Olivia K and Sabonis, Dziugas and Fedorova, Iana and Shi, Yun and Miraj, Gause and Le, Shuai and Deng, Jun and Zhu, Yuhao and Cai, Yanyao and Zhang, Chengqian and Arya, Garima and Dixon, Shelley A H and Angus, Steven P and Duerkop, Breck A and Liang, Haihua and Pepin, Robert H and Ve, Thomas and Bondy-Denomy, Joseph and Tamulaitiene, Giedre and Gerdt, Joseph P},
title = {Chemical inhibition of a bacterial immune system},
journal = {Cell Host & Microbe},
year = {2026},
volume = {34},
number = {2},
pages = {263--277.e11},
doi = {10.1016/j.chom.2026.01.003}
}
EUVIMED